

December 28, 2017

To,  
**The Deputy General Manager**  
**Surveillance**  
**BSE Limited**  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai-400 001.

**BSE Scrip Code: 532637**

Dear Sir,

**Sub: Reply to your letter on increase in volume.**  
**Ref: Your letter no. L/SURV/ONL/PV/PA/2017-2018/229 dated December 28, 2017.**

"With reference to your letter dated December 28, 2017, we wish to inform you that the Company has made all the necessary disclosures of material information, wherever applicable, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. As required, we hereby confirm that, as of now, we do not have any material information or announcement to make that in our opinion would have a bearing on the price/volume behavior in the scrip.


Kindly take a note of the same.

Kindly let us know if we need to take any further actions in this regard."

Thanking You,

Your's faithfully,

For **Mangalam Drugs & Organics Ltd**

*Nikita Bavishi*  


Nikita Bavishi  
Company Secretary